A Randomized, Double-blind, Placebo-controlled Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-42847922 in Healthy Male and Female Subjects
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2017
Price : $35 *
At a glance
- Drugs Seltorexant (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- Sponsors Janssen-Cilag
- 21 Jan 2015 Preliminary results published in Minerva Neurosciences media release.
- 14 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 16 Oct 2014 Planned End Date changed from 1 Sep 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov record.